Finally, mechanistic studies, including the blockage of the IL-6/TGF-β axis, would be required to depict the mechanism by which MSC alleviates the imiquimod-mediated psoriasis-like skin inflammation. The gene discussed is TGFB1; the disease is psoriasis.